Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 2:07 AM
Ignite Modification Date:
2025-12-25 @ 2:07 AM
NCT ID:
NCT03298360
Brief Summary:
To analyze the HIV viral sequences present in the CD32 + CD4a + T lymphocytes of the patients who have participated in the ANRS 139 TRIO trial, always followed and in virological success, and carrying multi-resistant viruses archived in the HIV cell reservoir, in order to reconstruct the chronology of the installation of this reservoir.
Detailed Description:
Objectives
Principal objective
To analyze the HIV viral sequences present in the CD32 + CD4a + T lymphocytes of the patients who have participated in the ANRS 139 TRIO trial, always followed and in virological success, and carrying multi-resistant viruses archived in the HIV cell reservoir, in order to reconstruct the chronology of the installation of this reservoir.
Secondary objectives
To analyze the HIV viral sequences present in the CD4 + lymphocytes with other membrane HIV reservoir markers, currently being identified, in these same patients
Methodology
Pathophysiological study, in patients infected by multi drug-resistant viruses
Estimated enrollment
21 participants (total and per group)
Intervention
167mL blood sample in EDTA tube:
* 160mL (16 tubes of 10mL): for IGH (Institute of Human Genetics-Montpellier)
* 7mL (1tube of 7mL): to measure HIV-RNA in centers
Estimated planning or Study / Trial timetable
Study start date: September 2017
Enrollment period: 12 months
Total study duration: 24 months (analyses included)
Estimated study/trial completion date: September 2019 (one year after enrollment of the last patient)
Study design
Cross-sectional survey, 167mL of blood in EDTA tube will be obtained on a research visit, after signature of written informed consent
Study:
NCT03298360
Study Brief:
Protocol Section:
NCT03298360